Unmasking a new prognostic marker and therapeutic target from the GDNF-RET/PIT1/p14ARF/p53 pathway in acromegaly

BACKGROUND: Acromegaly is produced by excess growth hormone secreted by a pituitary adenoma of somatotroph cells (ACRO). First-line therapy, surgery and adjuvant therapy with somatostatin analogs, fails in 25% of patients. There is no predictive factor of resistance to therapy. New therapies are inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Chenlo, Miguel, Rodriguez-Gomez, Iria A., Serramito, Ramon, Garcia-Rendueles, Angela R., Villar-Taibo, Rocío, Fernandez-Rodriguez, Eva, Perez-Romero, Sihara, Suarez-Fariña, Maria, Garcia-Allut, Alfredo, Cabezas-Agricola, Jose M., Rodriguez-Garcia, Javier, Lear, Pamela V., Alvarez-San Martin, Rosa M., Alvarez-Escola, Cristina, Bernabeu, Ignacio, Alvarez, Clara V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562173/
https://www.ncbi.nlm.nih.gov/pubmed/30975543
http://dx.doi.org/10.1016/j.ebiom.2019.04.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562173/
https://www.ncbi.nlm.nih.gov/pubmed/30975543
http://dx.doi.org/10.1016/j.ebiom.2019.04.007

Ejemplares similares